ArticleInternational urology and nephrology2023
Trends in mortality and comorbidities in hemodialysis patients between 2012 and 2017 in an East-European Country: a retrospective study.
Article in International urology and nephrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Nutritional Challenges in Hemodialysis: A Perspective from Albania.The Eurasian journal of medicine · 2026Article
- Understanding the Drivers of Hypothyroidism in Patients Undergoing Chronic Hemodialysis.Diagnostics (Basel, Switzerland) · 2026Article
- The Application of Mobile Health in Self-Management Among Patients Undergoing Dialysis: Scoping Review.Journal of medical Internet research · 2026Article
- The Burden of Heart Failure in End-Stage Renal Disease: Insights from a Retrospective Cohort of Hemodialysis Patients.Journal of clinical medicine · 2025Article
- Travel Distance to Dialysis and Mortality Among Hemodialysis Patients in a Geographically Small Country.Journal of community health · 2025Article
- Article
- Metabolic-Nutritional Associations with Depression in Elderly Chronic Kidney Disease Patients: Hemodialysis Versus Non-Dialysis Populations.Metabolites · 2025Article
- Association of serum resolvin D1 with the risk of major adverse cardiovascular events in hemodialysis patients.International urology and nephrology · 2025Article
- Impact of nutritional status and pulmonary function on short- and long-term overall survival in hemodialysis patients.PloS one · 2025Article
- Article
- Prospective Study of Change in Skin Autofluorescence Over Time and Mortality in People Receiving Hemodialysis.Kidney international reports · 2024Article
- Early Detection of Inflammation and Malnutrition and Prediction of Acute Events in Hemodialysis Patients through PINI (Prognostic Inflammatory and Nutritional Index).Diagnostics (Basel, Switzerland) · 2024Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to evidence trends and changes in mortality, comorbid conditions, prognosis, and causes of death after 5 years of continuous evolution of hemodialysis (HD) patients in Romania.
methodsWe included two cohorts of stable HD patients (901 from 2012 and 1396 from 2017). Both cohorts were followed up for 1 year. The 5-year survivors of the 2012 cohort were identified in 2017 and their data changes were assessed.
resultsThe 2017 patients were older, with longer time on dialysis, higher serum creatinine and urea levels, and required higher ultrafiltration volume per dialysis. They also had lower hemoglobin, lower C-reactive protein, higher albumin, higher calcium bicarbonate, and higher parathyroidectomy prevalence. The 2017 cohort presented with lower average dialysis flow, less administration of iron sucrose, had more catheters, lower hepatitis C prevalence, higher diabetes mellitus prevalence, higher heart valve calcifications, higher heart rate disorders, higher prevalence of left ventricular hypertrophy, and lower ejection fraction. Cardiovascular disease was the main cause of death in both years (50% in 2012 and 45.6% in 2017), followed by sepsis and cancer. The mortality was higher in 2017 compared to 2012 (14.1 vs 6.6%). The 5-year mortality was 37.2% with an average of 7.44%/year. The risk of death increased with age, higher C-reactive protein, higher phosphate, lower hemoglobin, and lower albumin.
conclusionCardiovascular disease remains the main causes of death in HD-treated patients but with decreasing trend. Developing regional therapeutic strategies for quality care with early intervention will most likely improve mortality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.